Ursodeoxycholic acid


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Dissolution of cholesterol-rich gallstones
Adult: 8-12 mg/kg once daily at bedtime or in 2 divided doses. May continue for up to 2 years depending on stone size and composition. Treatment is continued for 3-4 months after radiological disappearance of gallstones. Dosage recommendations may vary among individual products and between countries (refer to specific product guidelines).

Oral
Primary biliary cirrhosis
Adult: 12-16 mg/kg daily in 2-4 divided doses for the 1st 3 months, then may be given as once daily in the evening thereafter. Dosage recommendations may vary among individual products and between countries (refer to specific product guidelines).

Oral
Hepatobiliary disorder associated with cystic fibrosis
Child: As oral susp: ≥1 month 20 mg/kg daily to be given in 2-3 divided doses, may increase up to 30 mg/kg daily as necessary. As cap or tab: ≥6 years 20 mg/kg daily to be given in 2-3 divided doses, may increase up to 30 mg/kg daily as necessary. Dosage recommendations may vary among individual products and between countries (refer to specific product guidelines).

Oral
Prophylaxis of gallstones in patients undergoing rapid weight loss
Adult: As cap: 600 mg daily as a single or in 2 divided doses.
Nhóm bệnh nhân đặc biệt
Dissolution of cholesterol-rich gallstones:
In obese patient: Up to 15 mg/kg daily may be needed.
Cách dùng
Should be taken with food.
Chống chỉ định
Acute inflammation of gallbladder or biliary tract, biliary tract occlusion (common bile duct or cystic duct), frequent episodes of biliary colic, radio-opaque calcified gallstones, impaired contractility of gallbladder, gallstone pancreatitis or biliary-gastrointestinal fistula, non-functioning gallbladder, inflammatory bowel disease; hepatic and intestinal conditions interfering with enterohepatic recirculation of bile acids (e.g. extrahepatic and intrahepatic cholestasis, ileal resection and stoma, regional ileitis); active duodenal and gastric ulcer; unsuccessful portoenterostomy or without recovery of normal bile flow in children with biliary atresia. Acute, chronic or severe hepatic impairment.
Thận trọng
Patients with non-visualising gallbladder, variceal bleeding, hepatic encephalopathy, ascites. Obese patients. Children. Pregnancy and lactation.
Phản ứng phụ
Significant: Biliary obstruction.
Gastrointestinal disorders: Diarrhoea, pasty stools, nausea, vomiting, constipation, dyspepsia; rarely, severe right upper abdominal pain (if used for primary biliary cirrhosis).
Hepatobiliary disorders: Rarely, calcification of gallstones, decompensation of liver cirrhosis.
Musculoskeletal and connective tissue disorders: Back pain.
Nervous system disorders: Headache, dizziness.
Respiratory, thoracic and mediastinal disorders: Upper respiratory tract infection.
Skin and subcutaneous tissue disorders: Urticaria, pruritus.
Chỉ số theo dõi
Monitor liver function tests (e.g. AST, ALT, γ-GT) as clinically necessary. If used for the dissolution of gallstone, perform oral cholecystography and ultrasound periodically. Evaluate pregnancy status before initiation of therapy.
Quá liều
Symptoms: Diarrhoea. Management: Symptomatic treatment with fluid and electrolyte balance restoration, may use ion-exchange resins to bind bile acids in the intestines.
Tương tác
May reduce absorption and efficacy with bile acid-binding resins (e.g. colestyramine, colestipol), antacids (e.g. aluminium hydroxide, aluminium oxide), charcoal. May increase absorption and serum concentration of ciclosporin. May reduce absorption of ciprofloxacin, nitrendipine. Increased hepatic cholesterol secretion and reduced efficacy with estrogen hormones, oral contraceptives, blood cholesterol-lowering agents (e.g. clofibrate). May increase serum concentration of rosuvastatin.
Tác dụng
Description: Ursodeoxycholic acid is a naturally occurring bile acid. It reduces cholesterol secretion from the liver and fractional reabsorption of the cholesterol by the intestine resulting in decreased cholesterol content of the bile and bile stones.
Synonym: UDCA, Ursodiol.
Pharmacokinetics:
Absorption: Rapidly absorbed from the gastrointestinal tract.
Distribution: Enters breast milk. Plasma protein binding: Approx 70%.
Metabolism: Undergoes extensive enterohepatic recycling, partly conjugated in the liver prior to biliary excretion. Under the influence of intestinal bacteria, the free and conjugated forms undergo 7α-dehydroxylation to lithocholic acid; some of which are further conjugated and sulfated hepatically.
Excretion: Via faeces; urine (<1%). Elimination half-life: Approx 3.5-5.8 days.
Đặc tính

Chemical Structure Image
Ursodeoxycholic acid

Source: National Center for Biotechnology Information. PubChem Database. Ursodeoxycholic acid, CID=31401, https://pubchem.ncbi.nlm.nih.gov/compound/Ursodeoxycholic-acid (accessed on Jan. 23, 2020)

Bảo quản
Store below 30°C.
Phân loại MIMS
Thuốc thông mật, tan sỏi mật & bảo vệ gan
Phân loại ATC
A05AA02 - ursodeoxycholic acid ; Belongs to the class of bile acids. Used in bile therapy.
Tài liệu tham khảo
Anon. Ursodiol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 13/04/2021.

Buckingham R (ed). Ursodeoxycholic acid. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 13/04/2021.

Joint Formulary Committee. Ursodeoxycholic acid. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 13/04/2021.

Reltone 200 mg, 400 mg Capsule (Intra-Sana Laboratories). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 15/04/2021.

Ursodeoxycholic Acid 250 mg Capsules, Hard (AS Grindeks). MHRA. https://products.mhra.gov.uk. Accessed 13/04/2021.

Ursodeoxycholic Acid 500 mg Tablets (TEVA UK Limited). MHRA. https://products.mhra.gov.uk. Accessed 13/04/2021.

Ursodiol Tablet (BluePoint Laboratories). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 15/04/2021.

Ursofalk 250 mg/5 mL Suspension (Dr Falk Pharma UK Ltd). MHRA. https://products.mhra.gov.uk. Accessed 13/04/2021.

Ursosan 250 mg Hard Capsules (PharmEng Technology Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 13/04/2021.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Ursodeoxycholic acid từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • DaewoongUrsa 100 mg
  • Dourso
  • Homan
  • pms-Ursodiol C
  • Udihep
  • Urdoc
  • Uromix
  • Ursa 200 mg
  • Ursalgan
  • Ursilon
  • Ursocholic
  • Ursolisin
  • Ursolvan
  • Uruso
  • Winudihep
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in